EGFR and lung carcinoma: Interestingly in lung cancer cells which harbor an activating mutation in EGFR (HCC827) we observed that high percentage of the LysRS are phosphorylated at position s207 (Figure 1D), implying that at least in vitro, aberrant activation of EGFR can lead to over-activation of the LysRS pathway.